Peptipedia
BioregulatorPreclinicalAnimal Studies

Veslugen

A peptide bioregulator designed to support vascular and circulatory function. Part of the Khavinson synthesized peptide bioregulator family.

Preclinical research, approved in Russia as supplement
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

10-20 mg daily

Frequency

Once or twice daily

Duration

10-30 day cycles

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 10-20 mg daily via Oral capsules or sublingual, Once or twice daily. Dose range: 10-20 mg daily. Duration: 10-30 day cycles.

Timing & Administration

Administer via Oral capsules or sublingual. Frequency: Once or twice daily.

Mechanism of Action

Modulates gene expression in vascular tissue, supporting endothelial cell function and vessel health by penetrating cells to influence DNA transcription patterns.

Research Summary

Evidence level: animal studies. Clinical status: Preclinical research, approved in Russia as supplement.

Side Effects & Safety

Important Warnings

  • Not FDA approved
Generally well-tolerated
limited safety data outside Russia

References

No references available.

Related Peptides

Browse all →
LivagenBioregulator

A tetrapeptide bioregulator (Lys-Glu-Asp-Ala) developed by Khavinson that modulates chromatin structure. Studies in elderly subjects (75-88 years) showed activation of ribosomal genes.

View profile
OvagenBioregulator

A tripeptide bioregulator targeting liver and gastrointestinal tissue, derived from liver tissue extracts. Modulates gene expression related to detoxification, antioxidant defense, and cellular repair.

View profile
CortagenBioregulator

A tetrapeptide bioregulator (Ala-Glu-Asp-Pro) derived from cerebral cortex extracts. Studied for neuroprotection, neural differentiation, and cognitive support.

View profile